Ann: AnteoTech Signs Australian Distribution Agreement for EuGeni, page-130

Excellent video. My quick summary of the points Derek made about the saliva testing. I think this completely clears up a lot of the speculation/argument/bed-wetting that's been going on in a number of other posts:

Point 1: When the antigen is present in saliva our test works perfectly. We have no issue with detecting the antigen with our test in saliva.

Point 2: Mouth saliva is slightly different to nasal mucous. What we’re trying to do is detect the antigen with mouth saliva. But at different points in the mouth or in different areas of the mouth, there are different viral conditions or different viral loads. There are some points which have a commensurate viral load or a load that is close to nasal mucous, and there are other points of the mouth that have a much lower viral load or no viral load whatsoever. We cannot detect the antigen when there is no viral load - it’s just not there. So we have to be very careful about the use case or how we harvest from the mouth because there is a great amount of variability in the different ways you can harvest the samples from the mouth.

Point 3: People put things in their mouth that they don’t put into their nose. Those things can affect the viral load and where the virus exists in the mouth. So it is quite challenging in that the viral load changes because people put food and drink in their mouth, which makes the harvesting process slightly more complicated.

Point 4: We are obligated as a legal manufacturer of a test for SARS-CoV-2 to make sure that we provide an instruction for use that makes sure the test works consistently. If we don’t do that our reputation will be extremely damaged and the test simply won’t work the way we want it to work. We can’t risk that - we have to make sure we get it right.

Evaluations that have been underway:

1. Evaluations started in the UK. That was an extremely successful evaluation for us. It gave us a lot of data, enabled us to understand how to set up our subsequent studies.
2. This data took us to further studies in Spain and Australia.
3. We currently have 3 separate evaluation studies underway in India which we expected to finish around the end of June. Despite 38,000 positive cases per day, we can only operate effectively from a couple of sites which we have been doing the last couple of months, but over the last few weeks the number of positive cases has been slowing at these sites as they are coming out of a lockdown. So we are seeing a slowdown in the amount of data coming out that will flow into finalising our evaluation studies out of india. Unfortunately this means we’ve eclipsed the timelines which we originally announced to the market.